CRH Medical Corp (CRHM) Upgraded to “Outperform” at RBC Capital Markets
CRH Medical Corp (NASDAQ:CRHM) was upgraded by equities research analysts at RBC Capital Markets from a “sector perform” rating to an “outperform” rating in a research note issued on Monday. The brokerage presently has a $8.50 price target on the stock, up from their prior price target of $7.00. RBC Capital Markets’ price objective would indicate a potential upside of 53.15% from the stock’s current price.
CRHM has been the topic of a number of other research reports. Zacks Investment Research lowered CRH Medical Corp from a “buy” rating to a “hold” rating in a research note on Monday, September 5th. Canaccord Genuity set a $6.00 price target on CRH Medical Corp and gave the stock a “buy” rating in a research note on Thursday, October 27th. Finally, CIBC restated an “outperform” rating on shares of CRH Medical Corp in a research note on Tuesday, September 13th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $6.31.
CRH Medical Corp (NASDAQ:CRHM) opened at 5.55 on Monday. The stock has a 50 day moving average of $5.14 and a 200 day moving average of $4.07. CRH Medical Corp has a 52 week low of $2.15 and a 52 week high of $6.30.
COPYRIGHT VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/29/crh-medical-corp-crhm-downgraded-by-rbc-capital-markets-to-sector-perform.html.
Large investors have recently modified their holdings of the company. TFS Capital LLC acquired a new stake in shares of CRH Medical Corp during the second quarter worth $138,000. Counsel Portfolio Services Inc. purchased a new stake in shares of CRH Medical Corp during the second quarter worth approximately $485,000. Morgan Stanley raised its stake in shares of CRH Medical Corp by 335.9% in the third quarter. Morgan Stanley now owns 157,800 shares of the company’s stock worth $601,000 after buying an additional 121,600 shares in the last quarter. Palladium Partners LLC raised its stake in shares of CRH Medical Corp by 109.5% in the third quarter. Palladium Partners LLC now owns 221,900 shares of the company’s stock worth $845,000 after buying an additional 116,000 shares in the last quarter. Finally, Ativo Capital Management LLC purchased a new stake in shares of CRH Medical Corp during the second quarter worth approximately $1,076,000.
CRH Medical Corp Company Profile
CRH Medical Corporation, formerly Medsurge Medical Products Corp., is a healthcare products and services company. The Company operates through segments, including the sale of medical products and the provision of anesthesia services. The Company specializes in the treatment of hemorrhoids utilizing its treatment protocol and technology.
Receive News & Stock Ratings for CRH Medical Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical Corp and related stocks with our FREE daily email newsletter.